NOVKAN — Novakand Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK5.40m
- -SEK10.67m
Brief: Kancera Signs Letter Of Intent Agreement With Recardio For Licensing Of Kand567, Kand145
Brief: Kancera: Intention To Change Company Name To Novakand Pharma
Brief: Kancera Q4 Operating Result SEK 9.9 Mln
Brief: Kancera Q3 Operating Loss Widens To SEK 11.5 Mln
Brief: Kancera Focuses On Fractalkine Blocking Candidate Drugs KAND567 And KAND145
Brief: Kancera Q2 Operating Loss Narrows To SEK 11.4 Million
Brief: Kancera Gives Operational Update Concerning Its Clinical Development Program
Brief: Kancera Withdraws Incentive Programme Proposal
Brief: Kancera Q1 Operating Loss Narrows To SEK 13.4 Mln
Brief: Kancera Meets Primary Objectives Of Kand145 Clinical Phase I Study
Brief: Kancera Raises About SEK 73.0 Mln Through Rights Issue
Brief: Kancera Resolves On Rights Issue Of About SEK 121.9 Mln
Brief: Kancera Q4 R&D Expenses Amounted To SEK 17.1 Mln
Brief: Kancera Signs License Agreement, Obtains Global Commercial Rights To Results From Fractal Study
Brief: Kancera Presents Statistical Analysis From The Fractal Study
Brief: Kancera Reports Positive Results From Fractal Study
Brief: Kancera: Preclinical Projects ROR1 And PFKFB3 Are Discontinued
Brief: Kancera Q3 Operating Loss Sek 10.5 Million
Brief: Kancera Q2 Operating Loss Widens To SEK 18.3 Million